Integrated risk-informed AI-assisted weak signals screening solutions
Reinventing the future with integrated risk-informed AI-assisted detection of early weak signals.
Before cancer speaks, weak signals whisper
Our advanced patented technology leverages integrated trustworthy risk-informed AI to ensure multi-scale risk assessment and prediction, and uncertainties modeling and quantification, to ensure early detection of weak signals of rare events.
By characterizing new predictive risk markers and capturing subtle imperceptible early-stage signals across clinical, medical imaging, and multimodal data, HOPE VALLEY AI empowers the clinical research ecosystem, healthcare providers, and their patients to anticipate and assess risk exposure and cancer incubation, many years in advance, enabling proactive health monitoring, personalized prevention, and earlier medical response.
40%
of all diagnosed cancer cases are preventable and are associated with avoidable risk factors, such as alcohol consumption, and physical inactivity.
Source : Santé publique France, 2018
40%
of breast cancers occur in women who could have been identified as augmented-risk patients, several years prior to diagnosis
Source : Interception - Gustave Roussy
11%
5-year survival rate of pancreatic cancer all stages combined. It is expected to become the second deadliest cancer in France in 2040.
Source: Prof. Louis de Mestier (AP-HP)
Our Mission
Building integrated risk-informed AI-assisted solutions to empower patients to “Know their Normal” and help their healthcare providers, clinical researchers and industry to save lives and defeat cancer with integrated multi-scale risk prediction and AI-assisted detection of early weak signals of rare events before they occur.
Patients diagnosed at stage I benefit from substantially higher 5-year survival rates, up to 99% for breast cancer and 100% for lung cancer, compared to those diagnosed at stage IV, where survival drops to as low as 7%.
Moreover, the average cancer-related healthcare costs within one year of diagnosis escalate sharply with later-stage detection. For instance, treating prostate cancer at stage IV costs over $440,000, compared to $123,000 at stage I.
Similar patterns are seen across other cancer types, with costs multiplying two to six times between early and late-stage diagnoses. These figures underscore the critical importance of early screening and detection programs—not only for saving lives but also for ensuring more sustainable healthcare expenditure.
Early detection of cancer significantly increases the chances of survival while reducing the financial burden on healthcare systems.
This is HOPE
Breast Cancer is highly curable and it can be successfully treated if detected at an early stage. It can be even avoided through effective breast health education, awareness and prevention.
“Knowing My Normal” is the key component of the breast health awareness which is crucial to breast cancer risk prediction and early detection.
This is the heart of HOPE, the first smart breast health digital clinic on Smartphone, which will be available in October 2025 for all women over 25 and their primary healthcare providers.
This is MAMMOPE
MAMMOPE is an innovative AI-based ultrasound medical device, designed by Hope Valley AI with the support of the Design Spot Université Paris-Saclay, to address the issue of medical deserts by empowering primary healthcare providers with a smart non-operator-dependent ultrasound medical device.
It combines multimodal ultrasound with embedded AI to generate real-time, risk-informed breast imaging and a patented 4D digital twin of breast health. This enables continuous tracking of weak signals and offers a safe, radiation-free solution to support routine medical monitoring and preventive screening, used in complement and support of standard methods such as mammography and breast MRI.
This is IRISCREEN
IRISCREEN is a cutting-edge AI-assisted week signals screening platform designed by HOPE VALLEY AI to help researchers and industry partners gain a better understanding of the silent rare events’ incubation challenges, years before they occur.
Powered by integrated multi-scale risk-informed AI-based technology, IRISCREEN integrates multimodal data such as clinical, medical imaging, biological, and genetic data, to characterize new predictive risk markers and early detect weak signals of rare events’ incubation, long before symptoms appear.
Its first deployment in digital oncology targets pancreatic cancer, one of the deadliest cancers with a 5-year survival rate below 11% and a rising incidence in the World.
